All News

FDA notified healthcare professionals of serious health risks that have been reported in premature babies receiving lopinavir/ritonavir (Kaletra, Abbott) oral solution. Lopinavir/ritonavir oral solution contains the ingredients alcohol and propylene glycol.

FDA approved belimumab (Benlysta, Human Genome Sciences and GlaxoSmithKline) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus who are receiving standard therapy.

According to a survey published in the March issue of the Journal of Clinical Nursing, nearly two-thirds of hospital in-patients had experienced pain in the previous 24 hours, and 42% of those rated their pain as more than 7 out of 10.

FDA's Pulmonary-Allergy Drugs Advisory Committee voted to approve Novartis' QAB149 (indacaterol) 75 µg as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema, PR Newswire reported.

One pharmacist wonders how it is possible that during 2 shifts in a row last week, she encounters complete ignorance of the potentially deadly and needless combination of popular ED pills and nitrates.

Rheumatoid arthritis patients who have been treated with glucocorticoids have an increased risk of gastrointestinal perforation, according to a study published in Arthritis & Rheumatism.

Tifacogin does not appear to improve outcomes of patients with severe community-acquired pneumonia, according to a global study published online in the American Thoracic Society?s American Journal of Respiratory and Critical Care Medicine, ahead of the print edition.

A new study published in Science Translational Medicine found that patients? expectations regarding the effects of pain medications influence medication efficacy as well as the pain-related brain pathways activated during treatment.

U.S. Marshals acting on a request of FDA seized all lots of Auralgan otic solution from Integrated Commercialization Solutions in Brooks, Ky.

Children being treated with a short course of oral corticosteroids for an acute asthma attack may experience a brief and transient depression of their immune response, according to a recent study conducted by Université de Montréal.

A recent recall of generic warfarin tablets was expanded to include 6 other drug products prepared on the same packaging line.

The American College of Physicians recently issued 3 recommendations for use of intensive insulin therapy for the management of glycemic control in hospitalized patients.

FDA issued a complete response letter to EMD Serono, an affiliate of Merck KGaA, requesting additional information on cladribine (Movectro), a drug intended for the treatment of relapsing-remitting multiple sclerosis.

Sunitinib and everolimus improved progression-free survival in patients with advanced pancreatic neuroendocrine tumors, according to 2 recent studies published in the New England Journal of Medicine.

The rate of decline in the use of atypical antipsychotics in outpatients with dementia accelerated following a black box warning issued by FDA, according to "Trends in Antipsychotic Use in Dementia 1999-2007," a multicenter study of national Veterans Affairs data that appeared in the Archives of General Psychiatry.

Tranexamic acid reduces the risk of death from bleeding without increasing the risk of vascular occlusive events or the need for surgical intervention, according to a review published in the 2011 Cochrane Database of Systematic Reviews.

FDA has updated the pregnancy section of drug labels for the entire class of antipsychotic medications to provide more information about the potential risk of extrapyramidal signs and withdrawal symptoms in newborns whose mothers take antipsychotics during the third trimester of pregnancy.

FDA approved the first-and-only selective phosphodiesterase type 4 inhibitor roflumilast (Daliresp, Forest Pharmaceuticals), once-daily oral tablet to decrease the frequency of exacerbations or worsening of symptoms from severe chronic obstructive pulmonary disease.

FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.

Rheumatoid arthritis patients with a high body mass index respond less well to infliximab (Remicade, Centocor Inc.), according to a new study published in Arthritis & Rheumatism.

In a new study of medication administration at nursing homes and residential homes, administration errors were 4 times as likely to occur with liquids than with medications given by dispensers and other monitored dosage systems.

Black-box warnings or safety labels on drugs differed widely across drugs and drug classes, according to a new study published in the Journal of Internal Medicine.

A new study published in The Lancet found that medication for lowering blood pressure in hypertensive stroke patients might be harmful and has little benefit.

In the White House Budget, President Barack Obama targets the high cost of prescription drugs and proposes 2 significant changes for improving consumer access to less-expensive generic drugs.

NACDS and NCPA authored a joint letter to Senate Armed Services Committee Chairman Carl Levin (D-Mich.), emphasizing the ability of community pharmacies to help lower prescription drug costs, and the importance of maintaining the right of military families and veterans to choose where they fill their prescriptions through the TRICARE program.

FDA approved azilsartan medoxomil tablets (Edarbi, Takeda Pharmaceutical North America) to treat hypertension in adults.

FDA notified healthcare professionals that neither injectable nor oral terbutaline be used by pregnant women for prevention of preterm labor due to risk of serious maternal heart problems and death.

Bisphosphonates such as Fosamax and Boniva may reduce patients? risk of developing colon cancer, according to a new study published in the Journal of Clinical Oncology.

Merck Serono Europe informed the European Medicines Agency that it was withdrawing its marketing authorization application for oral cladribine (Movectro), 10-mg tablets, intended for the treatment of relapsing-remitting multiple sclerosis.

Forest Laboratories $1.2 billion acquisition of Clinical Data, the developer of Viibryd (vilazodone HCl) for the treatment of adults with major depressive disorder, is expected to allow Forest to leverage its existing presence in the antidepressant category.